Today's health developments span metabolic risks linked to sleep loss, innovations in IBD monitoring, cognitive benefits of physical activity in elderly populations, advances in pediatric emergency care triage, and regulatory actions on pharmaceuticals.

Sleep restriction for just six weeks led to increased weight gain, waist circumference, and elevated leptin levels in adults with cardiometabolic risk, highlighting the metabolic consequences of even mild sleep loss.

Implementation of intestinal ultrasound services reduced endoscopies for inflammatory bowel disease activity assessment by over 50%, offering a less invasive alternative for monitoring IBD progression.

Elderly 'super movers' aged 80+ who walk at faster speeds demonstrate approximately 50% lower risk of cognitive impairment despite no reduction in underlying Alzheimer's disease pathology, suggesting physical activity's protective cognitive effects.

A new prediction model successfully identifies children with anaphylaxis at low risk of requiring additional epinephrine treatment, potentially enabling safe management outside emergency departments and reducing unnecessary hospitalizations.

Bioprosthetic heart valves show favorable delivery outcomes for women of childbearing age undergoing aortic valve replacement, offering important guidance for pregnancy planning in this population.

The DEA proposed scheduling synthetic 7-OH kratom products as Schedule I controlled substances while permitting most botanical kratom to remain unregulated, balancing drug safety concerns with traditional product availability.

FDA strengthened safety warnings for alopecia areata medication Litfulo, restricting its use to patients without suitable alternative treatments due to emerging safety concerns.

A network meta-analysis of 19 weight-loss drugs found that most obesity medications fail to meaningfully improve quality of life or cardiovascular health outcomes, raising questions about their broader therapeutic value beyond weight reduction.